Davis Polk advised Credit Suisse Securities (USA) LLC and Piper Jaffray & Co. as joint book-running managers in connection with the $48.0 million initial public offering of 3,000,000 shares of common stock of Adamas Pharmaceuticals, Inc. The common stock is listed on the NASDAQ Global Market under the symbol “ADMS.” 

Based in Emeryville, California, Adamas is a specialty pharmaceutical company focused on chronic disorders of the central nervous system. Adamas enhances the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing its lead wholly owned product candidate, ADS-5102, for a complication of Parkinson’s disease known as levodopa induced dyskinesia and as a treatment for chronic behavioral symptoms associated with traumatic brain injury.

The Davis Polk corporate team included partner Bruce K. Dallas, associates Danielle Moore Burton and Bryan M. Quinn and former associate Nicholas J. Dashman. The tax team included partner Rachel D. Kleinberg and associates Catherine Paskoff Chang and Patrick E. Sigmon. The intellectual property team included associates Natalie A. Thomas and Jansen A. S. Thurmer. Counsel Cynthia Akard provided executive compensation advice. Counsel Marcie A. Goldstein provided FINRA advice. Counsel Catherine L. Martin provided Investment Company Act advice. Members of the Davis Polk team are based in the Menlo Park, New York and Washington DC offices.